MMP20

Across TCGA pan-cancer cohorts, MMP20 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MMP20 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MMP20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MMP20 expression acts as an unfavorable survival marker.

LUAD, ESCA, and SARC are the cancer types where MMP20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.158	0.750	<.001	25	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	18	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MMP20–LUAD (OS)

Open the LUAD breakdown →